The impact of reducing cardiovascular medication copayments on health spending and resource utilization

Journal of the American College of Cardiology

Volumn 60, Issue 18, 2012, Pages 1817-1824

  Choudhry, Niteesh K ^a   Fischer, Michael A ^a   Avorn, Jerry L ^a   Lee, Joy L ^a   Schneeweiss, Sebastian ^a   Solomon, Daniel H ^a   Berman, Christine ^b   Jan, Saira ^c   Lii, Joyce ^a   Mahoney, John J ^b   Shrank, William H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Pitney Bowes Inc   (United States)

^c HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY   (United States)

Author keywords

coronary artery disease; cost of health care; evidence based medicine; health reform; insurance coverage; pharmaceuticals

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

ARTICLE; CARDIOVASCULAR SYSTEM; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; EMERGENCY WARD; EMPLOYER; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SERVICE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK REDUCTION; SOCIAL STATUS; VASCULAR DISEASE;

AGED; CARDIOLOGY; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COST SHARING; DRUG THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH CARE COSTS; HEALTH CARE REFORM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, HEALTH; INTERVENTION STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84867850477     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.06.050     Document Type: Article

References (20)

1. N.K. Choudhry Promoting persistence: improving adherence through choice of drug class Circulation 123 2011 1584 1586
2. M.E. Chernew, I.A. Juster, M. Shah Evidence that value-based insurance can be effective Health Aff (Millwood) 29 2010 530 536
3. N.K. Choudhry, M.B. Rosenthal, A. Milstein Assessing the evidence for value-based insurance design Health Aff (Millwood) 29 2010 1988 1994
4. Patient Protection and Affordable Care Act, HR 3590, § 2713(c) (2010).
5. A.M. Fendrick, D.G. Smith, M.E. Chernew, S.N. Shah A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost Am J Manag Care 7 2001 861 867
6. M.E. Chernew, M.R. Shah, A. Wegh Impact of decreasing copayments on medication adherence within a disease management environment Health Aff (Millwood) 27 2008 103 112
7. A.B. Rosen, M.B. Hamel, M.C. Weinstein, D.M. Cutler, A.M. Fendrick, S. Vijan Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes Ann Intern Med 143 2005 89 99
8. N.K. Choudhry, A.R. Patrick, E.M. Antman, J. Avorn, W.H. Shrank Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries Circulation 117 2008 1261 1268
9. N.K. Choudhry, J. Avorn, E.M. Antman, S. Schneeweiss, W.H. Shrank Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis Health Aff (Millwood) 26 2007 186 194
10. T.B. Gibson, J. Mahoney, K. Ranghell, B.J. Cherney, N. McElwee Value-based insurance plus disease management increased medication use and produced savings Health Aff (Millwood) 30 2011 100 108
11. T.B. Gibson, S. Wang, E. Kelly A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses Health Aff (Millwood) 30 2011 109 117
12. N.K. Choudhry, J. Avorn, R.J. Glynn Full coverage for preventive medications after myocardial infarction N Engl J Med 365 2011 2088 2097
13. N.K. Choudhry, M.A. Fischer, J. Avorn At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence Health Aff (Millwood) 29 2010 1995 2001
14. S. Schneeweiss, J.D. Seeger, M. Maclure, P.S. Wang, J. Avorn, R.J. Glynn Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data Am J Epidemiol 154 2001 854 864
15. M.B. Buntin, A.M. Zaslavsky Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures J Health Econ 23 2004 525 542
16. P.M. Ho, E.D. Peterson, L. Wang Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome JAMA 299 2008 532 539
17. N.K. Choudhry, R. Levin, J. Avorn The economic consequences of non-evidence-based clopidogrel use Am Heart J 155 2008 904 909
18. P.S. Chan, M.R. Patel, L.W. Klein Appropriateness of percutaneous coronary intervention JAMA 306 2011 53 61
19. A.K. Wagner, S.B. Soumerai, F. Zhang, D. Ross-Degnan Segmented regression analysis of interrupted time series studies in medication use research J Clin Pharm Ther 27 2002 299 309
20. S. Schneeweiss, M. Maclure, S.B. Soumerai, A.M. Walker, R.J. Glynn Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance J Clin Epidemiol 55 2002 833 841